Oracle Q4 Beat: Strong Growth, But Market Remains Skeptical on Conversion and Financing

What happened

Oracle's Q4 FY2026 results exceeded consensus, with revenue jumping 21% to $19.18B and adjusted EPS of $2.11. The company highlighted a stunning $638B performance obligation backlog, up from $552.6B three months earlier, and guided FY2027 revenue to $90B, above expectations. However, the stock failed to rally, reflecting investor concerns that the massive backlog is heavily back-end loaded—only about 12% is expected to convert to revenue within 12 months—while capital expenditure and financing needs remain elevated. The beat reinforced the central tension: demand is soaring, but the pace of capacity deployment and cash flow generation lags, leaving the equity priced for rapid conversion that has yet to materialize.

Implication

The Q4 results and $638B RPO headline might tempt bulls, but the lack of price appreciation signals that sophisticated investors are pricing in the same duration and funding risks highlighted in our DeepValue analysis. The $90B FY2027 revenue guide implies an acceleration of OCI conversion, but with only ~12% of RPO due in the next 12 months and trailing free cash flow deeply negative at -$24.7B, the path to that outcome requires flawless execution and continued favorable capital markets. We wait for observable evidence that capacity throughput is accelerating (e.g., >400MW/quarter) and that 0-24 month RPO conversion is rising above ~18%. Until then, we see $215 as fair value in our base case, with downside to $170 if delivery slippage or funding stress materializes. Trim above $255; accumulate near $185.

Thesis delta

The massive RPO increase from $552.6B to $638B confirms demand momentum but simultaneously lengthens the duration of the backlog—the 0-12 month conversion share remains at ~12%, so the larger backlog is weighted even more to out-years. This shift reinforces our existing thesis: Oracle's value depends on converting contracted demand into cash sooner, not just accumulating bigger backlog numbers. The market's muted reaction to the beat supports our 'WAIT' rating: the equity already prices in successful conversion, but the operating data show the conversion is not yet keeping pace with the backlog expansion. The thesis therefore remains unchanged: we need to see the next 10-Q showing a meaningful pull-forward in RPO timing and a stabilization of financing requirements to turn constructive.